Neostigmine is destroyed by plasma esterases, and the quaternary alcohol and parent compound are excreted in the urine.
Neostigmine methyl sulfate is an arylammonium sulfate salt. It has a role as an EC 188.8.131.52 (cholinesterase) inhibitor. A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.